A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Iván O. Rosas(Brigham and Women's Hospital), Augustine M.K. Choi(Cornell University), Rie Maurer(Brigham and Women's Hospital), Gary M. Hunninghake(Hubei University of Science and Technology), Roberto F. Machado(University of Maryland, Baltimore), Ganesh Raghu(University of Washington), Hilary J. Goldberg(Harvard University), Danielle Teller(Harvard University), Souheil El‐Chemaly(AVEO Oncology (United States)), David J. Lederer(Regeneron (United States)), Joe G. N. Garcia(Scripps Research Institute), Harold R. Collard(University of California, San Francisco), Elizabeth Peters(Cornell University), Joseph A. Lasky(Tulane University), Imre Noth(University of Virginia), Fernando J. Martínez(University of Massachusetts Chan Medical School), Kevin R. Flaherty(University of Michigan)
Cited by 97
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome
|Nature Immunology|2010|3k
Autophagy in Human Health and Disease
|New England Journal of Medicine|2013|2.6k